[1] | World Health Organization Cardiovascular diseases (CVDs). Fact sheet. Reviewed September 2016. Available at http://www.who.int/mediacentre/factsheets/fs317/en/ Accessed on 28/10/2016. |
[2] | Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries. Curr Probl Cardiol. 2010; 35(2): 72–115. |
[3] | Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012; 6(4): 325-30. |
[4] | World Health Organization. Global Health Observatory (GHO) data. 2016. Available at http://www.who.int/gho/en/ Accessed on 28/10/2016. |
[5] | Oguejiofor O C, Onwukwe C H, Odenigbo C U. Dyslipidemia in Nigeria: Prevalence and pattern. Ann Afr Med 2012; 11:197-202 |
[6] | Raal FJ, Med M. Pathogenesis and Management of the Dyslipidemia of the Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 2009; 7(2): 83-88. |
[7] | Report of WHO Scientific Group. Cardiovascular disease risk factors: New areas for research. WHO Technical Report Series No 841. Geneva: WHO; 1994. Available at http://apps.who.int/iris/bitstream/10665/37644/1/WHO_TRS_841.pdf Accessed on 28/10/2016. |
[8] | European Atherosclerosis Society. International Task Force for prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr Metab Cardiovascular Dis 1992; 2:113-56. |
[9] | Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13; 110(2):227-39. |
[10] | NutritionMD.org:: Hyperlipidemia: References 2016. Available athttp://www.nutritionmd.org/health_care_providers/cardiovascular/hyperlipidemia_references.html Accessed on 29/10/2016. |
[11] | Anyabolu EN, Chukwuonye II, Arodiwe E, Ijoma CK, Ulasi I. Prevalence and predictors of chronic kidney disease in newly diagnosed human immunodeficiency virus patients in Owerri, Nigeria. Indian J Nephrol 2016; 26:10-5. |
[12] | Anyabolu EN, Chukwuonye II, Mabayoje M, Ejike A, Ijoma CK, Oviasu E, Kadiri S.. Comparison of Spot Urine Protein/Creatinine Ratio, Spot Urine Protein/Osmolality Ratio with Measured 24-Hour Urine Protein in HIV Subjects in Nigeria. J AIDS Clin Res 2015; 6: 445. doi:10.4172/2155-6113.1000445. |
[13] | Ernest Ndukaife Anyabolu. Body Mass Index and Associated Factors of Obesity and Underweight in a General Out-patient Population in a Tertiary Hospital in Nigeria. American Journal of Internal Medicine. 2016; 4(5): 85-92. |
[14] | WHO (1995) Physical Status: The Use and Interpretation of Anthropometry. Technical Report Series 854, 1-1-9950. World Health Organization, Geneva. Available at http://www.who.int/childgrowth/publications/physical_status/en/ Accessed on 29/10/2016. |
[15] | Yeh HC, Lin YS, Kuo CC, Weidemann D, Weaver V, Fadrowski J et al. Urine osmolality in the US population: implications for environmental biomonitoring. Environ Res. 2015 Jan; 136:482-90. |
[16] | Anyabolu EN, Chukwuonye II. Urine Osmolality in Adults Attending a General out-Patient Clinic: Clinical Implications, American Journal of Medicine and Medical Sciences. 2016; 6(5): 145-151. |
[17] | Hemoglobin concentrations for the diagnosis of anemia and assessment of severity VMNIS | Vitamin and Mineral Nutrition Information System WHO/NMH/NHD/MNM/11.1. Available athttp://www.who.int/vmnis/indicators/haemoglobin/en/ Accessed on 29/10/2016. |
[18] | Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486. |
[19] | Odenigbo CU, Oguejiofor OC, Odenigbo UM, Ibeh CC, Ajaero CN, Odike MA. Prevalence of dyslipidaemia in apparently healthy professionals in Asaba, South South Nigeria. Nig j Clin Pract 2008; 11:330-5. |
[20] | Osuji CU, Nzerem BA, Meludu S, Dioka CE, Nwobodo E, Amilo GI. The prevalence of overweight/obesity and dyslipidaemia amongst a group of women attending "August" meeting. Niger Med J 2010; 51:155-9. |
[21] | Sani MU, Wahab KW, Yusuf BO, Gbadamosi M, Johnson OU, Gbadamosi A. Modifiable cardiovascular risk factors among apparently healthy adult Nigerian population-a cross sectional study. BMC Research notes 2010; 3:11. |
[22] | Yang W, Xiao J, Yang Z, Ji L, Jia W, Weng J, Lu J, et al. Serum Lipids and Lipoproteins in Chinese Men and Women. Circulation. 2012; 125(18):2212-2221 |
[23] | Joshi S, Anjana RM, Deepa M, Pradeepa R, Bhansali A, et al, for the ICMR– INDIAB Collaborative Study Group. Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study. PLOS ONE. May 9, 2014; Available at http://dx.doi.org/10.1371/journal.pone.0096808 Accessed on 28/09/2016. |
[24] | Hu FB, Wang B, Chen C, Jin Y, Yang J, Stampfer M, et al. Body Mass Index and Cardiovascular Risk Factors in a Rural Chinese Population. Am J Epidemiol 2000; 51:88-97. |
[25] | Achari V, Sharmak KK. Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. Indian Heart J. 2014 May; 66(3): 280–288. |
[26] | Enas EA. Clinical implications: Dyslipidaemia in the Asian Indian population. Information Available from http://www.southasianheartcentre.org/dois/AAPLmonograph.pdf Accessed on 28/09/2016. |
[27] | Kondo A, Li J, Manabe M, Saito K, Kanno T, Maekawa M. Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations. J Atheroscler Thromb. 2003; 10(2): 72-8. |
[28] | Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, et al. Triglycerides and Cardiovascular Disease. A Scientific Statement from the American Heart Association. Circulation. 2011; 123:2292-2333. http://dx.doi.org/10.1161/CIR.0b013e3182160726 Accessed on 28/09/2016. |
[29] | Baliga KV, Sharma PK, Prakash MS, Mostafi M. Lipid Profile In Transplant Patients: A Clinical Study. MJAFI 2002; 58: 32-35. |
[30] | Shoji T, Masakane I, Watanabe Y, Iseki‖ K, Tsubakihara Y, for the Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. Elevated Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. CJASN 2011; 6(5): 1112-1120. |
[31] | Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. July 2016; 90(1): 41–52. |
[32] | Adu E.M. Serum lipid profile abnormalities among patients with nephrotic. Int J Med Biomed Res 2013; 2(1): 13-17. |
[33] | Ozdemir A, Sevinc C¸ Selamet U, Turkmen F. The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. Am J Med Sci 2007; 334:331-3. |
[34] | Zaribaf F, Entezari MH, Hassanzadeh A, Mirzaian S. Association between dietary iron, iron stores, and serum lipid profile in reproductive age women. J Educ Health Promot 2014; 3:15. |
[35] | Bankir L, Plischke M, Bouby N, Haas M. Urine Osmolarity and Risk of Dialysis Initiation in a CKD Cohort. Ann Nutr Metab 2015; 66(suppl 3): 14-17. |
[36] | Waldo HB, Mariana de Paz S, Matilde N, Marisa L, Aeiel G. Impaired Urine Dilution Capability in HIV Stable Patients. Int J Nephrol. 2014; 17: 9(11), e111949. Available at http://dx.doi.org/10.1155/2014/381985 Accessed on 29/10/2016. |
[37] | Popkin BM, D’Anci KE, Rosenberg IH. Water, Hydration and Health. Nutr Rev. 2010; 68(8): 439–458. |
[38] | Perucca J, Bouby N, Valeix P, Bankir L: Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 2007; 292: R700-R705. |
[39] | Winnett G, Cranfield L, Almond M. Apparent renal disease due to elevated creatinine levels associated with the use of boldenone. Nephrol Dial Transplant (2010) 1-3 doi: 10.1093/ndt/gfq663. Accessed on 28/09/2016. |
[40] | Vaziri ND: Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003; 63:1964 –1976. |
[41] | Trevisan R, Dodesini AR, Lepore G. Lipids and Renal Disease. JASN April 2006 vol. 17 no. 4 suppl 2 S145-S147. |
[42] | Granata A, Insalaco M, Di Pietro F, Di Rosa S, Romano G, Scuderi R. Atheroembolism renal disease: diagnosis and etiologic factors. Clin Ter. 2012 Jul; 163(4): 313-22. |